Adherence to Antiretroviral Therapy (ART) among People Living With HIV (PLHIV): a cross-sectional survey to measure in Lao PDR
© Hansana et al.; licensee BioMed Central Ltd. 2013
Received: 29 November 2012
Accepted: 24 June 2013
Published: 28 June 2013
Since 2001, antiretroviral therapy (ART) for people living with HIV (PLHIV) has been available in the Lao People’s Democratic Republic (PDR). A key factor in the effectiveness of ART is good adherence to the prescribed regimen for both individual well-being and public health. Poor adherence can contribute to the emergence of drug resistant strains of the virus and transmission during risky behaviors. Increased access to ART in low-income country settings has contributed to an interest in treatment adherence in resource–poor contexts. This study aims to investigate the proportion of adherence to ART and identify possible factors related to non-adherence to ART among people living with HIV (PLHIV) in Lao PDR.
A cross-sectional study was conducted with adults living with HIV receiving free ART at Setthathirath hospital in the capital Vientiane and Savannakhet provincial hospitals from June to November 2011. Three hundred and forty six PLHIV were interviewed using an anonymous questionnaire. The estimation of the adherence rate was based on the information provided by the PLHIV about the intake of medicine during the previous three days. The statistical software Epidata 3.1 and Stata 10.1 were used for data analysis. Frequencies and distribution of each variable were calculated by conventional statistical methods. The chi square test, Mann–Whitney test and logistic regression were used for bivariate analyses. Multiple logistic regression analysis was conducted to determine the predictors of non-adherence to ART. A p-value < 0.05 was considered to indicate statistical significance.
Of a total of 346 patients, 60% reported more than 95% adherence to ART. Reasons for not taking medicine as required were being busy (97.0%), and being forgetful (62.2%). In the multivariate analysis, educational level at secondary school (OR=3.7, 95% CI:1.3-10.1, p=0.012); illicit drug use (OR=16.1, 95% CI:1.9-128.3, p=0.011); dislike exercise (OR=0.6, 95% CI:0.4-0.9, p=0.028), and forgetting to take ARV medicine during the last month (OR=2.3, 95% CI:1.4-3.7, p=0.001) were independently associated with non-adherence.
Non-adherence to ART was associated with individual factors and exposure to ART. Priority measures to increase adherence to ART should aim to intensify counseling and comprehensive interventions, such as guidance for PLHIV on medication self-management skills, tailoring the regimen to the PLHIV life style, and improving adherence monitoring and health care services.
KeywordsAntiretroviral therapy Adherence PLWHIV Self-report Lao PDR
The introduction of antiretroviral therapy (ART) and multidrug regimens, or highly active antiretroviral therapy (HAART) has substantially improved the survival of persons infected with HIV. These drug regimens however are complex. This, alongside issues of toxicity, side-effects, disruptions to patient’s daily life and difficulties in returning for scheduled follow-up consultations, often makes maintaining adherence over the long term challenging. Yet the individual and public health benefits of ART are adherence dependent. Inadequate adherence results in antiretroviral agents not being maintained at sufficient concentrations to suppress HIV replication in infected cells to lower the plasma viral load. In addition, suboptimal adherence can accelerate development of drug-resistant HIV and mitigate ART’s role in reducing HIV incidence and transmission. Promoting adherence is especially important as these treatments become increasingly available and affordable for people living with HIV (PLHIV) in developing countries where viral load monitoring is not usually possible [1, 2]. Consequently, more attention is being focused on issues related to ART adherence.
The importance of ART adherence makes accurate compliance assessment essential for effective and efficient therapy and evaluation of treatment regimens [3, 4]. There are a number of key issues in the study of ART adherence including having an accurate measure of adherence [5–7]. Measurement of adherence is usually based on Paterson’s pioneer study found that up to 95% adherence is necessary for effective HIV viral suppression . This measurement is usually obtained by using either a continuous or categorical variable constructed from patient self-reported adherence that distinguishes “optimal” from “sub-optimal” adherence based on the 95% threshold [8–10]. A limitation of this method is it only reflects short-term or average adherence and may be an over-estimation. Nevertheless, studies have demonstrated a significant relationship between self-report data and viral load [8–10].
Besides accurate measurement, other factors of importance in the study of ART adherence include sassessment of the impact of adherence on viral load and clinical outcome, identification of the factors that affect adherence and effective interventions. Understanding the factors that affect non-adherence could provide valuable information about patients most at risk. Studies suggest that factors associated with adherence can be grouped under four main categories. One relates to patient factors, for example demographic characteristics . Another relates to psychological parameter knowledge, personal skills. A third category relates to treatment regimen-related factors such as years on treatment, pill burden, side effects; provider-related factors including the patient-provider relationship . The fourth category relates to environmental and social factors such as supervision of treatment, HIV-related stigma and social support [6, 13]. While some factors determining non-adherence to ART may be similar across countries, others may be highly contextual, and culture or country specific [7, 8].
Most ART adherence studies have been undertaken in high-income countries [5–7]. Few studies have assessed adherence rates or predictors in low-or lower-middle income countries. This paper presents the findings of a study which investigated adherence to ART and possible factors related to non-adherence among PLHIV receiving ART in two public health facilities in the Lao People’s Democratic Republic (PDR), a lower-middle income country in South East Asia. As far as the authors are aware, this is the first such study in Lao PDR. The study fills a critical gap in understanding ART adherence in Lao PDR and contributes to the growing adherence research in low-income countries. Such studies are vital to ensure decisions about adherence interventions are informed by empirical support.
The prevalence of HIV among adults in Lao PDR is low (0.3%) , nevertheless, the number of PLHIV is increasing. It is estimated that approximately 10,000 people are living with HIV in Lao PDR with the first case identified in 1990 . The first specific HIV/AIDS project in Lao PDR was started by Medecins San Frontiers (MSF) in Savannakhet province, in 2001. This program offered free service, prophylaxis and treatment for opportunistic infections (OIs), and ART . Presently, there are five treatment centers and two satellite sites providing ART in the country. Two of these centers are in the capital Vientiane; two are in the southern provinces of Savannakhet and Champasack. The fifth center is in Luangphabang province in the north. There are also two satellite sites in the north (Borkeo and Luangnamtha provinces), also in the north and funded by the Global Fund to fight AIDS, TB and Malaria (GFATM). While the program has extended since the first case was identified, accesses to treatment for PLHIV by the end of 2011, total of 1,988 adults and children PLHIV who were in need have received ART. This is equivalent to 52.3% of estimated PLHIV eligible for ARV have received ART, a small increase compare to 50.8% in 2010 . For 2010 and 2011, despite continuous increase in the absolute number of PLHIV who received ART, the percentage rate dropped due to change in calculation for estimate eligible PLHIV for ART .
This study was conducted at the Setthathirath, tertiary level hospital located in the Vientiane capital and Savannakhet provincial hospital. These two geographical areas have the greatest HIV burden and are currently the two main sites providing free ART and related health care services. These facilities were selected as they were the most established clinics providing ART in Lao PDR, had a pool of HIV-infected patients on ART and were willing to participate in the study. At the time of the study in Savannakhet provincial hospital 1,447 HIV patients were registered of which 1,106 were receiving ART medicines . In Setthathirath hospital 821 HIV patients were registered of which 595 were on ART .
Study design and participants
This cross-sectional study was performed from January to March 2011 in Savannakhet and Sethathirath hospitals. Participants in the study were PLHIV receiving free ART provided by the HIV/AIDS care unit. To be included participants had to be 18 years or over and willing to participate in the study. The clinical condition of the patient had to be suitable for ART based on the CD4 count and to be in the WHO clinical stage for at least three months. The PLHIV were responsible for how and when to take the medicine.
PLHIV receiving ART were selected consecutively from both study sites by using probability proportional to size, based on the number of PLHIV who were on ART. The participants were selected using simple random sampling. Participants were drawn either from the PLHIV on ART list at the care unit or during a visit to the HIV/AIDS care unit for counseling and/or ART medication. The initial sample size was estimated to be 305 with a power of 0.84. However, we were able to enroll 346 participants, 130 from Sethathirath hospital and 216 from Savannakhet provincial hospital, 150 were recruited from the PLHIV on ART list and 196 came for regular visit. Four respondents declined to be interviewed as part of the study.
Adherence measurement in this study was based on patient recall of their compliance of the prescribed doses in the three days prior to the interview. Adherence was calculated based on the number of pills reported to have been actually taken divided by the number of prescribed pills over in the past three days. Patients who reported an intake of ≥ 95% of the prescribed medication were considered adherent, those with a reported intake of < 95% were classified as non-adherent.
A face-to-face interview with PLHIV by two trained interviewers at the HIV/AIDS center was conducted using a structured, self-report questionnaire developed by the Adult AIDS Clinical Trials Group (AACTG)  and slightly modified after a pre-testing at Mahosot hospital, Vientiane Capital (N=30). The AACTG was developed based on previous adherence to medical regimen research and has been extensively used to measure ART adherence. The questionnaire asked patients to recall their medication intake in terms of their prescribed doses for the three days prior to the interview. It also collected demographic data and information about health behaviors, seriousness of the disease, side effects and adverse drug reactions. In addition, it asked about health service-related characteristics of the center providing ART. Prior to administration, the questionnaire was translated into Lao and back translated by an independent translator. To ensure confidentiality, all respondents were interviewed in a private room at the HIV/AIDS care unit by the trained interviewers.
The statistical software Epi data 3.1 and Stata 10.1 were used to perform the analysis. The dependent variable was adherence to ART. To assess factors associated with non-adherence to ART, univariate, bivariate and multivariate analyses were conducted. Univariate analysis used conventional statistical methods to calculate frequencies and distribution of each variable. The chi square test and the Mann–Whitney test as well as a logistic regression were used for bivariate analyses. Multivariate analyses were performed to identify factors associated with premarital sexual activities with only those variables with p<0.10 from the initial bivariate analyses included in the model and controlling for other confounders such as socio-demographic characteristics of the participants and health risk behaviors (smoking, drinking and doing exercise). A p-value < 0.05 was considered to indicate statistical significance.
The study was undertaken as part of a higher research degree at KhonKaen University, Thailand. The study protocol was approved by the Ethic Committee’s Declaration of the University of Health Sciences, Lao PDR and the Ethics Committee of the KhonKaen University, Thailand. The interviewer explained the purpose of the study and procedures and gained written informed consent before commencing the interview. The participants were also informed that their participation was voluntary and that they could withdraw from the interview/discussion at any time without consequences. The participants were assured that their responses would be treated in confidence and they were assured anonymity through the use of strict coding measures.
Socio-demographic characteristic of respondents
Mean: 36.5±7.6; Min: 20; Max: 66
Monthly income (Lao kip) (n=264)
Duration since HIV diagnosed (months)
Mean:46.7±30.1; Min: 3; Max: 168
No. of people living in the same house
Mean:4.7±2.3; Min: 1; Max: 15
Person(s) living in the same house
Disclosed HIV status
Health risk behavior characteristics
Health risk behaviors by sex of respondents
Alcohol drinking (last month )
Ever used illicit drug
Ever had multiple sex partners
Medical history and ART treatment
The number of patients who reported being admitted to the hospital after being infected with HIV due to poor health or opportunistic infection was 213(61.6%). The most common reasons for hospital admission were prolonged fever, TB/pneumocystis and chronic diarrhea. Most respondents (91.0%) reported they felt better since starting ART. Only two patients (0.6%) reported that their health had become worse after starting ART. Almost half 154, (44.5%) of the PLHIV were classified as being in the clinical HIV stage IV based on the WHO standard and the CD4 count. The mean CD4 count was 148.1±175.4 mm3 with a range of 2 to 934 with most respondents (88.7%) having CD4 cell counts of less than 350 mm3 which is the threshold to ART treatment according to the National guidelines . The mean duration of receiving ART was 38.2 ± 25.9 months, with 44.2% having started ART treatment in the 3 to 30 months prior to the survey. The result of this study found that the mean of duration of ART started was 38.2 months with a range from 3 to 99 months.
Level of non-adherence to ART
Medical history and ART of respondents
Medical history and ART treatment
Admitted to the hospital related to HIV infection
Reasons for hospital admittance (n=213)
Chronic herpes simplex infection
WHO clinical stage
CD4 at initiation of ART (n=326)
Mean148.1±175.4; Min: 2; Max: 934
Duration of ART (months)
Mean:38.2±25.9; Min: 3; Max: 99
Number of ARV medicines received
Health status since initiation of ART
Ever forgotten to take ARV medicine in the last month
Reasons for forgetting to take ARV medicine (n=135)
Too many pills/taste of medicine
Long distance to hospital
Run out of medicine
Severe symptoms/difficult to follow-up
Ever had side effects of ARV medicine
Ever missed an appointment
Factors associated with ART adherence
Factor associate with antiretroviral therapy (ART) adherence with in the past 3 days (n=346)
Adherence in past 3 days (%)
*Odds ratio (95% confidence interval)
Duration since HIV diagnosis (month)
Ever used illicit drugs
Forgot to take ARV medicine in the last month
Multivariate logistic regression model of factors associated with non-adherence to ART
After adjustment for established risk factors for non-adherence (Table 4), factors that remained significantly associated with non-adherence were education attainment at secondary school (OR= 3.7; 95% CI: 1.3-10.1, p = 0.012), illicit drug use (OR = 16.1; 95% CI: 1.9-128.3, p = 0.011), disliking exercise (OR = 0.6; 95% CI:0.4-0.9, p = 0.028), and forgetting to take ART medicine during the last month (OR=2.3; 95% CI:1.4-3.7, p = 0.001).
In this study, we examined factors associated with ART adherence in Lao PDR. Non-adherence usually means skipping one dose of medicine. Based on the self-report questionnaire, the study results indicated that more than half of the PLHIV had good adherence to ART defined as ≥95%. Nevertheless, 40% of respondents reported poor ART adherence. This is a concern given poor adherence severely compromises effectiveness and is linked with the likelihood of the drug resistance. Non-adherence to ART in this study was associated with socio-demographic characteristics, illicit drug use, and history of taking ART. In the final model in our sample, the variables educational level at secondary school, having used illicit drugs, having started ART within the last 31–60 months and forgetfulness played a significant role in predicting adherence to ART.
The finding of 60% ART adherence among PLHIV in our study is similar to that found in a study in Zambia and one in India [22, 23], but lower than studies China , and Vietnam . It is also lower than reported in studies conducted in developed countries using similar self-report measures [26, 27]. Some caution is needed in comparing adherence rates across studies however, as the methods of measuring adherence (self-report vs. pill counts or medication electronic monitoring system (MEMS) and settings such as free ART vs. non-free, rural vs. urban, plasma donor vs. injecting drug users or other risk groups) can affect findings. Measurement of ART adherence is also problematic as patients may overestimate their adherence due to recall bias, the demand characteristics of patient-provider consultation and the desire to avoid criticism .
In our study, reasons given for non-adherence related to being busy, forgetfulness and distance to the clinic. Other reasons given included running out of medication, having too many pills to take, the taste of the medication, severe side effects, difficulties in maintaining the medication regiment and self-stigma. Self-stigma may lead to patients being unwilling or fearful of taking medicine when other people are present . A qualitative study in Vietnam identified self-stigma as a pervasive barrier to ART adherence with patients concerned that taking medications in the presence of others could lead to unplanned disclosure of their HIV status . Forgetfulness was identified in our study as a significant variable in predicting adherence to ART. This is similar to a study in rural China . In the present study, we found a statistically significant association between non-adherence and secondary school educational level. Other studies have shown low levels of education as an important factor associated with non-adherence and a general barrier for medical care [29, 30]. In contrast, a study in Bangalore, India found education had no effect on adherence . This difference in findings may be due to our participant group in general being relatively well educated and thus more aware about the problems of sub-optimal treatment.
Illicit drug use has been associated with depression and anxiety, either as part of the withdrawal process or because of repeated use. This is particularly relevant in the treatment of HIV infection because depression is one of the strongest predictors of poor adherence and poor treatment outcomes . Our study found that illicit drug use was a contributing factor to non-adherence based on the 95% threshold. Illicit drug use has been reported to reduce the level of adherence in many studies [32–34]. Various studies have documented that widespread illicit drug use among PLHIV makes their treatment complicated and hinders their quality of life [4, 35]. It has also been suggested that less than 95% adherence when combined with illicit drug may lead to viral suppression .
Being on ART for 31–60 months was significantly associated with non-adherence to ART in this study. This finding is supported by Andreo C. et al. who found that where patients had been on ART medication for more than two years, increased non-adherence was observed . This could be because the longer patients are on treatment they become complacent and find it harder to follow the strict regimen. Research in Vietnam also identified that over time, family members who had initially played a supportive role in helping patients take their medication, assumed the PLHIV was taking their medication as prescribed and followed up with the patient less regularly . This factor may also be a contributing factor in decreased adherence over time.
Some studies have identified side effects of ART medications as significant barriers to good adherence . In this study, although half of the patients (52.3%) reported signs and symptoms of adverse reactions to their treatment, further analysis did not identify these factors as being significantly related to non-adherence. However, this might be due to the limitations of the methods used as both non-adherence and the adherence group reported having trouble with side effects. Nevertheless, it would seem to be a priority that ART programs should where possible, increase the availability of regimens with fewer adverse reactions.
In the present study, no difference in adherence levels based on the duration of taking ART and WHO clinical stages was observed. In addition, the CD4 count at the start of treatment did not significantly correlate with non-adherence to ART. A study in India demonstrated an association between self-reported adherence and improvement in CD4 counts . According to Sarna et al.,  lower improvement in CD4 counts during the early stages of taking ART medication may be due to a delay between virologic and immunologic failure.
The present study suggests that to increase ART compliance a number of strategies are required. There has been limited research however on the effectiveness of strategies to enhance adherence in low-income settings. Directly observed therapy (DOT) as used in tuberculosis treatment, has been used with ART with some effect but is resource intensive . In Vietnam, perceptions of stigma prevented home-based DOT being viewed as acceptable . Other interventions include limiting the size, number, side effects and frequency of pills taken per day. Such regimens are likely to be more attractive to patients trying to conceal their HIV status for fear of stigma .
Mobile phones can provide an inexpensive and convenient means of communication to support treatment compliance. Randomized controlled trials have found mobile phones to be an effective adherence support tool in in low-resource settings . A trial in Kenya for example found a weekly mobile phone text asking in the local language “how are you?” improved viral suppression outcomes when compared with care . In focus group interviews patients reported that the weekly messages made them feel that someone cared. Another trial found that short weekly one-way text messaging improved medication adherence whereas daily messaging did not . A study in Vietnam however, found that while there was overall acceptance of the use of mobile phones, stigma and fear of HIV disclosure were a barrier to use . In Lao PDR, mobile phones are sometimes used to contact the patients when they miss appointments but texting or other mobile phone functions are not currently used to encourage compliance. Given in the present study stigma was a barrier to optimal ART compliance and some HIV patients were also illegal drug-users, further research into the appropriateness of mobile phone use as a form of adherence support in Lao PDR is needed. Issues of confidentiality would also need to be addressed. Research would also be needed to identify the preferred types of mobile phone functions for adherence maintenance. Provider attention to developing a good relationship with the patient, taking time to address concerns about the medications and side-effects can improve adherence. Counseling, education and peer support are other interventions which have been identified as being effective . In Vietnam a randomized controlled trial found peer support improved quality of life and adherence after 12 months among ART patients presenting at clinical stages 3 and 4 at baseline, but had no impact on quality of life among ART patients enrolled at clinical stages 1 and 2 .
Limitations of study
The findings of this study must be interpreted in the light of its limitations. The study was conducted at only two sites in the country and the findings may not be generalizable to other clinical settings. There is no gold standard for measuring adherence and our measurement of adherence is based on PLHIV self-reports of missed doses which may be subject to social desirability and recall biases. The literature for example, suggests that PLHIV tend to overestimate adherence . However, many other studies document that well collected self-reported data clearly correlate with virologic change and is more practical in most settings . A meta-analysis of several studies demonstrated a good correlation between self-reported medication adherence and virologic outcomes and that self-reported lower non-adherence to be more reliable than self-reported higher adherence [45, 46]. Further, in the present study, adherence information was collected by the non-clinical research staff so there was less reason for participants to over-report adherence. We were also unable to relate the obtained adherence rate to CD4 cell count due to financial and logistical barriers to frequent laboratory monitoring, a limitation common in low and low-middle income countries.
It is also possible that selection bias occurred, as only those PLHIV who were on ART at the time of data collection were included, whereas those who were lost-to-follow up or could not attend the clinic to collect medication were excluded. The cross-sectional design of this study means we could only estimate levels of adherence at one point in time while adherence to medication is a dynamic process and participants’ behavior may change over time. In addition, the design means that casual relationships between ART non-adherence and other correlates cannot be identified and we can only demonstrate association between levels of education, illicit drug use, duration since the initiation of ART and non-adherence. Additionally, we collected PLHIV consecutively attending the care units over a limited time. Finally, the focus of this research was on individual patient factors affecting adherence. Additional research is needed to better understand heath care provider and health care system determinants of treatment adherence.
The high level of non-adherence to ART found in this study (40%) is a public health concern. In view of the serious implications of non-adherence for public health, there is a critical need for targeted intervention strategies that increase the level of adherence. Non-adherence to ART in this study was associated with socio-demographic characteristics, illicit drug use, and history of taking ART. The findings of this study suggest there is a need increase the strategies used to promote adherence. It is likely that a range of interventions is needed, including increasing education, counseling, guidance on medication self-management skills and tailoring the regimen to PLHIV life styles. The feasibility of low–cost technologies such as mobile phones should also be explored. Improving adherence health care monitoring including guidelines for health care workers on monitoring adherence and strengthening peer and family support can also be effective strategies. Qualitative research is also required to understand contextual factors in identifying the optimal mix of support interventions and for who. Evaluation is also required of any interventions aimed at increasing ART to better understand cost effective measures in low-income settings.
The authors would like to thank the China Medical Board for their financial support. We are also grateful to all PLHIV who took part in this study, without them this publication would not have been possible. Special thanks were expressed to the health staff of the HIV/AIDS care unit of both Setthathirath and Savannakhet Provincial Hospitals for their kind cooperation.
- UNAIDS: AIDS Epidemic Update. 2009, http://www.unaids.org/en/dataanalysis/knowyourepidemic/epidemiologypublications/2009aidsepidemicupdate/. (Accessed October 28, 2010)Google Scholar
- Bangsberg DR, Moss AR, Deeks SG: Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004, 53: 696-699. 10.1093/jac/dkh162.View ArticlePubMedGoogle Scholar
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133 (1): 21-30.View ArticlePubMedGoogle Scholar
- WHO: Adherence to Long-Term Therapies - Evidence for action. 2003, Geneva: World Health OrganizationGoogle Scholar
- Malta M, Petersen ML, Clair S, Freitas F, Bastos FI: Adherence to antiretroviral therapy: a qualitative study with physicians from Rio de Janeiro, Brazil. Cad Sude Publica. 2005, 21 (5): 1424-32. 10.1590/S0102-311X2005000500015.View ArticleGoogle Scholar
- Simoni JM, Frick PA, Pantalone DW, Turner BJ: Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med\. 2003, 11: 185-198.PubMedGoogle Scholar
- Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, et al: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006, 368 (9547): 1587-94. 10.1016/S0140-6736(06)69118-6.View ArticlePubMedGoogle Scholar
- Sabin LL, Desilva MB, Hamer DH, Keyi X, Yue Y, Wen F, et al: Barriers to adherence to antiretroviral medications among patients living with HIV in southern China: a qualitative study. AIDS Care. 2008, 20 (10): 1242-50. 10.1080/09540120801918651.View ArticlePubMedPubMed CentralGoogle Scholar
- Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA: Self-Report Measure of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management. AIDS behave. 2006, 10 (3): 227-10.1007/s10461-006-9078-6.View ArticleGoogle Scholar
- Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al: Correlates and predictors of adherence to highly active antiretroviral therapy : Overview of published literature. Jaids J Acquir Immune Defic Syndr. 2002, 31: 123-127.View ArticleGoogle Scholar
- Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al: Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HER study. J AIDS. 2001, 28: 124-131.Google Scholar
- Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB: Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004, 19 (11): 1096-1103. 10.1111/j.1525-1497.2004.30418.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Catz SL, Kelly JA, Bogart LM, Benotsch EG, Mcauliffe TL: Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Heal Psychol. 2000, 19: 124-133.View ArticleGoogle Scholar
- National Committee for the Control of AIDS: National Strategic and Action Plan on HIV/AIDS/STI Control and Prevention 2011–2015. December 2010. 2010, Lao People’s Democratic RepublicGoogle Scholar
- MSF in Laos: Medicins Sans Frontieres; 2007 [updated 2007; cited 11/04/10]. 2010, Available from: https://www.doctorswithoutborders.org/publications/ar/report.cfm?id=3029&cat=activity-report. (Accessed March 14, 2010)Google Scholar
- UNICEF: Rapid Assessment: Most-at-Risk Adolescent and Young People to HIV in Lao PDR. 2011Google Scholar
- GARP: Global AIDS Response Progress Country Report. 2012, Lao PDRGoogle Scholar
- Savannakhet Health Department: Secretariat of STIs and HIV/AIDS Prevention and Control Unite (PCCA) Savannakhet Province. 2007, Lao People's Democratic Republic: Ministry of HealthGoogle Scholar
- HIV/AIDS care Unit: Annual Report on HIV/AIDS statistics Sethathirat hospital. 2009, Lao PDR: Ministry of HealthGoogle Scholar
- Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al: Self-report adherence to antiretroviral medications among participants in HIV clinical trials: AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000, 12 (3): 255-266. 10.1080/09540120050042891.View ArticlePubMedGoogle Scholar
- Ministry of Health, Lao PDR: National guidelines for the use of Antiretroviral Therapy in adults and children in Lao PDR. 2008, SecondGoogle Scholar
- Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AKS, et al: Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS. 2005, 9 (8): 526-37.View ArticleGoogle Scholar
- Birbeck GL, Chomba E, Kvalsund M, Bradbury R, Masng’ombe C, Malama K, et al: Antiretroviral Adherence in rural Zambia: The First Year of Treatment Availability. AmJTrop Med Hyg. 2009, 80 (4): 669-674.Google Scholar
- Wang XQ, Wu ZY: Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China. AIDS. 2007, 21 (8): 149-155.View ArticleGoogle Scholar
- Tran BX, Houston S: Mobile Phone-Based Antiretroviral Adherence Support in. 2012, Feasibility, Patient’s Preference, and Willingness-to-pay. AIDS Behav: VietnamGoogle Scholar
- Chesney MA: The Elusive Gold Standard: Future Perspectives for HIV Adherence Assessment and Intervention. Jaids J Acquir Immune Defic Syndr. 2006, 43 (1): 149-155.View ArticleGoogle Scholar
- Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, et al: Limited patients adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001, 161: 1962-1968. 10.1001/archinte.161.16.1962.View ArticlePubMedGoogle Scholar
- Tam VV, Pharris A, Thorson A, Alfven T, Larsson M: It is not that I forget, it’s justthat I don’t want other people to know”: barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care. 2011, 23 (2): 139-145. 10.1080/09540121.2010.507741.View ArticlePubMedGoogle Scholar
- Gao X, Nau DP: Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother. 2000, 34: 1117-1122.View ArticlePubMedGoogle Scholar
- Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL: Substance use and mental health correlates of non-adherence to antiretroviral medications n a sample of patients with human immune deficiency virus infection. Am J Med. 2003, 114 (7): 573-580. 10.1016/S0002-9343(03)00093-7.View ArticlePubMedGoogle Scholar
- Cauldbeck MB, O’Connor C, O’Connor MB, Saunders JA, Rao B, Mallesh VG, et al: Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Research and Therapy. 2009, 6 (7): 1-8.Google Scholar
- Moralez R, Figueiredo VM, Sinkoc MCB, Gallani C, Tomazin SL: Adherence of patients with AIDS to treatment with HAART medications: difficulties related and proposition of attenuating measures. 1998, Geneva: 12th World AIDS Conference, Abstract 42442Google Scholar
- Kalichman SC, Catz S, Ramachandran VS: Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 2000, 91 (8): 439-446.Google Scholar
- Wang HZJ, Li X, Yang A, Chen X, Fennie KP, William AB: Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central China. AIDS Patient Care STDS. 2008, 22 (1): 71-80. 10.1089/apc.2007.0047.View ArticlePubMedGoogle Scholar
- Sodergard B, Halvarsson M, Tully MP, Mindouri S, Nordstrom ML, Linback S, et al: Adherence to treatment in Swedish HIV-infected patients. J Clin Pharm Ther. 2006, 31 (6): 605-616. 10.1111/j.1365-2710.2006.00782.x.View ArticlePubMedGoogle Scholar
- Andreo C, Bertholon DR, Bouhnik AD, Rossert H, Soletti J, Spire B, et al: Non compliance in HIV-infected patients, supported by a community association. Sante Public. 2001, 13 (3): 249-262. 10.3917/spub.013.0249.View ArticleGoogle Scholar
- Mohammed H, Kieltyka L, Richardson-Alston G, Magnus M, Fawal H, Vermund SH, et al: Adherence to HAART among HIV-infected Persons in Rural Louisiana. AIDS Patient Care & STDs. 2004, 18 (5): 289-296. 10.1089/108729104323076025.View ArticleGoogle Scholar
- Sarna A, Pujari S, Sengar AK, Garg R, Gupta I, van Dam J: Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008, 127: 28-36.PubMedGoogle Scholar
- Raizada N, Chauhan LS, Babu BS, Thakur R, Khera A, Wares DF, et al: Linking HIV-Infected TB Patients to Cotrimoxazole Prophylaxis and Antiretroviral Treatment in India. PLoS One. 2009, 4 (6): e5999-10.1371/journal.pone.0005999.View ArticlePubMedPubMed CentralGoogle Scholar
- Horvath T, Azman H, Kennedy GE, Rutherford GW: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012, 3: CD009756. Epub 2012/03/16Google Scholar
- Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al: Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010, 376: 1838-45. 10.1016/S0140-6736(10)61997-6.View ArticlePubMedGoogle Scholar
- Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walgue D, et al: Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011, 25: 825-34. 10.1097/QAD.0b013e32834380c1.View ArticlePubMedPubMed CentralGoogle Scholar
- Nieuwkerk PT, Oort FJ: Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic response. J Autoimmune Defic Syndr. 2005, 38: 445-8. 10.1097/01.qai.0000147522.34369.12.View ArticleGoogle Scholar
- Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB: Adherence to antiretroviral medication among HIV-positive patients in Thailand. Jaids J Acquir Immune Defic Syndr. 2006, 43: 119-122. 10.1097/01.qai.0000230294.29699.c0.View ArticleGoogle Scholar
- Wood E, Kerr T, Tyndal MW, Montaner JSG: A review of barriers and facilitators of HIV treatment among injection drug user. AIDS. 2008, 22 (11): 1247-1256. 10.1097/QAD.0b013e3282fbd1ed.View ArticlePubMedGoogle Scholar
- Liu H, Golin C, Miller L, Hays RD, Beck K, Sanandaji S, et al: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001, 134: 968-77. 10.7326/0003-4819-134-10-200105150-00011.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/13/617/prepub